HLA-B* 1502 screening: time to clinical practice.
Locharernkul
Chaichon
C
Shotelersuk
Vorasuk
V
Hirankarn
Nattiya
N
D000483:Alleles; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D044466:Asian People / Q000235:genetics*; D002220:Carbamazepine / Q000009:adverse effects / Q000627:therapeutic use; D004827:Epilepsy / Q000188:drug therapy; D005819:Genetic Markers; D005820:Genetic Testing / Q000706:statistics & numerical data*; D005838:Genotype; D015235:HLA-B Antigens / Q000235:genetics*; D059910:HLA-B15 Antigen; D006801:Humans; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D013262:Stevens-Johnson Syndrome / Q000175:diagnosis / Q000235:genetics*
D000927:Anticonvulsants; D005819:Genetic Markers; D015235:HLA-B Antigens; C483536:HLA-B*15:02 antigen; D059910:HLA-B15 Antigen; D002220:Carbamazepine